



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> :  C07D 205/08		A1	(11) International Publication Number: <b>WO 95/01961</b>
			(43) International Publication Date: 19 January 1995 (19.01.95)
(21) International Application Number: PCT/US94/07291		(74) Agent: MAGATTI, Anita, W.; Schering-Plough Corporation, Patent Department K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).	
(22) International Filing Date: 1 July 1994 (01.07.94)			
(30) Priority Data: 08/089,357 9 July 1993 (09.07.93)		US	(81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KG, KR, KZ, LK, LV, MD, MG, MN, NO, NZ, PL, RO, RU, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD).
(60) Parent Application or Grant (63) Related by Continuation US Filed on 08/089,357 (CIP) 9 July 1993 (09.07.93)			
(71) Applicant (for all designated States except US): SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033 (US).		Published <i>With international search report.</i>	
(72) Inventors; and (75) Inventors/Applicants (for US only): THIRUVENGADAM, Tiruvettipuram, Kannapan [IN/US]; 14 Lavender Drive, Edison, NJ 08820 (US). McALLISTER, Timothy [US/US]; Apartment 3U, 5 Tulip Drive, Fords, NJ 08863 (US). TANN, Chou-Hong [US/US]; 30 Pinewood Crescent, Berkeley Heights, NJ 07922 (US).			

(54) Title: PROCESS FOR THE SYNTHESIS OF AZETIDINONES

## (57) Abstract

This invention provides a process for preparing azetidinones useful as intermediates in the synthesis of penems and as hypocholesterolemic agents, particularly for azetidinones substituted in the C-3 and C-4 positions and optionally substituted at the ring nitrogen, comprising reacting a  $\beta$ -(substituted-amino)amide, a  $\beta$ -(substituted-amino)acid ester, or a  $\beta$ -(substituted-amino)thiolcarboxylic acid ester with a silylating agent and a cyclizing agent.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

## PROCESS FOR THE SYNTHESIS OF AZETIDINONES

### 10 Background

This invention relates to a process for producing azetidinones useful as hypocholesterolemic agents and as intermediates for the synthesis of penems.

WO 93/02048 discloses stereoselective processes for 15 producing azetidinones. One process for preparing azetidinones wherein the substituents at the C-3 and C-4 positions have trans relative stereochemistry comprises cyclizing a hydroxyamide prepared from a carboxylic acid, an aldehyde and an amine in a process using an oxazolidinone as a chiral auxiliary. The disclosed process comprises the 20 following steps:

- (a) reacting a carboxylic acid with a chlorinating agent;
- (b) deprotonating a chiral oxazolidinone, preferably R-(+)-4-benzyloxazolidinone, with a strong base or a tertiary amine base and treating the resulting anion with the product of step (a);
- 25 (c) enolizing the product of step (b) with either:
  - (i) a dialkylboron triflate and a tertiary amine base; or
  - (ii)  $TiCl_4$  and tetramethylethylenediamine (TMEDA) or a mixture of TMEDA and triethylamine,
- then condensing with an aldehyde;
- 30 (d) hydrolyzing the product of step (c) with a base and hydrogen peroxide;
- (e) condensing the product of step (d) with an amine by treating with a dehydrative coupling agent, optionally adding an activating agent; and
- 35 (f) cyclizing the product of step (e) by reacting the product of step (e) with:
  - (i) a dialkylazodicarboxylate and a trialkylphosphine; or
  - (ii) a di- or tri-chlorobenzoyl chloride, an aqueous solution of a base and a phase transfer catalyst, then treating the resulting di-

- 2 -

or tri-chlorobenzoate with an aqueous solution of a base and a phase transfer catalyst; or  
(iii) a dialkylchlorophosphate, an aqueous solution of a base and a phase transfer catalyst; or  
5 (iv) a di- or tri-chlorobenzoyl chloride and a metal hydride.

In another process of WO 93/02048, an azetidinone having trans relative stereochemistry as described above is prepared by cyclizing a  $\beta$ -aminoamide derivative prepared from a carboxylic acid and an imine in a process using an oxazolidinone, preferably S-phenyl-oxazolidinone, 10 as a chiral auxiliary. This process comprises the steps:

- (a) reacting a carboxylic acid with a chlorinating agent;
- (b) deprotonating a chiral oxazolidinone, preferably S-phenyl-oxazolidinone, with a strong base or a tertiary amine base and treating the resulting anion with the product of step (a);
- 15 (c) enolizing the product of step (b) with  $TiCl_4$  and tetramethyl-ethylenediamine (TMEDA), then condensing with an imine; and
- (d) cyclizing the product of step (c) by treating with a strong non-nucleophilic base, preferably an alkali metal bistrimethylsilylamine.

20 Summary of the Invention


This invention provides a simple, high-yielding process for producing azetidinones under neutral conditions. Azetidinones are useful as hypocholesterolemic agents, as disclosed in WO 93/02048 and PCT International Application No. PCT/US94/00421, and are also useful as 25 intermediates in the synthesis of penems, a known group of antibacterials. This process is applicable for preparing azetidinones which are optionally mono-, di- or unsubstituted at each of the C-3 and C-4 positions and substituted at the ring nitrogen. The stereochemistry of C-3, C-4-disubstituted azetidinones prepared by this process is dependent on the 30 starting material: racemic, stereospecific or enantiomeric compounds can be obtained when the corresponding starting materials are used. In particular, this process is useful for the stereospecific preparation of azetidinones substituted in the C-3 and C-4 positions, and optionally substituted at the ring nitrogen.

35 In its broadest aspect, this invention relates to a process for preparing an azetidinone comprising reacting a  $\beta$ -(substituted-amino)-amide, a  $\beta$ -(substituted-amino)acid ester, or a  $\beta$ -(substituted-amino)-thiolcarboxylic acid ester with a silylating agent and a cyclizing agent.

- 3 -

More particularly, this invention relates to a process for preparing an azetidinone comprising reacting a silylating agent and a fluoride ion catalyst cyclizing agent with a suitably protected compound selected from the group consisting of

5        i) a  $\beta$ -(substituted-amino)amide, wherein the carbamoyl portion is B-C(O)-, wherein B is a deprotonated chiral auxiliary selected from the group consisting of




wherein X is -O-, -S- or -N(C<sub>1</sub>-C<sub>6</sub> alkyl)-; Y is =O or =S; and R<sup>12</sup> and R<sup>13</sup> are independently selected from the group consisting of C<sub>1</sub>-C<sub>6</sub> alkyl, phenyl, naphthyl, substituted phenyl, substituted naphthyl, lower alkoxy-carbonyl and benzyl, wherein the substituents on the phenyl and naphthyl are 1-3 substituents selected from the group consisting of lower alkyl, phenyl and benzyl, or wherein one of R<sup>12</sup> or R<sup>13</sup> is as defined above and the other is hydrogen; or B is (R<sup>14</sup>)(R<sup>15</sup>)N-, wherein R<sup>14</sup> and R<sup>15</sup> are independently selected from the group consisting of lower alkyl, aryl and benzyl;

10      ii) a  $\beta$ -(substituted-amino)acid ester, wherein the carboxylic acid ester portion is R<sup>14</sup>-O-C(O)-, wherein R<sup>14</sup> is lower alkyl, aryl or benzyl; and

15      iii) a  $\beta$ -(substituted-amino)thiolcarboxylic acid ester, wherein the thiolcarboxylic acid ester portion is R<sup>14</sup>-S-C(O)-, wherein R<sup>14</sup> is lower alkyl, aryl or benzyl.

20      Alternatively, when B is a deprotonated chiral auxiliary as defined above, the cyclization can be effected by the addition of a monovalent salt of the chiral auxiliary, i.e., a compound of the formula




25      wherein X, Y, R<sup>12</sup> and R<sup>13</sup> are as defined above and Z is selected from the group consisting of quaternary ammonium cations, such as arylalkyl-alkylammonium, aryl-alkylammonium and tetraalkylammonium, or mixtures thereof, and alkali metals. Examples of arylalkyl-alkylammonium groups are benzyltriethyl-ammonium and benzyl-trimethylammonium;

- 4 -

examples of aryl-alkyl-ammonium are phenyltriethylammonium and phenyltrimethyl-ammonium; typical tetraalkylammonium groups contain alkyl groups of 1-6 carbon atoms, e.g., tetra n-butylammonium; and typical alkali metals are sodium, potassium, cesium and lithium.

5 The process using a starting material wherein the  $\beta$ - (substituted-amino)amide comprises a deprotonated chiral auxiliary as defined above in (i) can alternatively be used with a non-chiral auxiliary, i.e., an auxiliary as defined above wherein each of R<sup>12</sup> and R<sup>13</sup> are hydrogen. The process employing a non-chiral auxiliary in the starting 10 material can employ either a fluoride ion catalyst or a salt of a chiral or non-chiral auxiliary for cyclization. Also, a salt of a non-chiral auxiliary can be used as a cyclizing agent in a process using a starting material containing a chiral auxiliary.

A particularly preferred embodiment of this invention relates 15 to a process for preparing an azetidinone, especially a stereospecific azetidinones as disclosed in WO 93/02048 and PCT/US94/00421, represented by structural formula I



wherein

20 Q is hydrogen, lower alkyl, phenyl-(CH<sub>2</sub>)<sub>0-3</sub>- or (W- substituted)phenyl-(CH<sub>2</sub>)<sub>0-3</sub>;

R is phenyl, W-substituted phenyl, naphthyl, W-substituted naphthyl, benzodioxolyl, heteroaryl, W-substituted heteroaryl, benzofused heteroaryl and W-substituted benzofused heteroaryl, wherein heteroaryl is 25 selected from the group consisting of pyrrolyl, pyridinyl, pyrimidinyl, pyrazinyl, triazinyl, imidazolyl, thiazolyl, pyrazolyl, thienyl, oxazolyl and furanyl, and for nitrogen-containing heteroaryls, the N-oxides thereof;

R<sup>1</sup> and R<sup>2</sup> are independently selected from H or R;

W is 1 to 3 substituents independently selected from the 30 group consisting of lower alkyl, hydroxy lower alkyl, lower alkoxy, alkoxyalkyl, alkoxyalkoxy, alkoxy carbonylalkoxy, (lower alkoxyimino)-lower alkyl, lower alkylenedioyl, lower alkyl lower alkylenedioyl, allyloxy, -CF<sub>3</sub>, -OCF<sub>3</sub>, benzyl, R<sup>3</sup>-benzyl, benzyloxy, R<sup>3</sup>-benzyloxy, phenoxy, R<sup>3</sup>-phenoxy, dioxolanyl, NO<sub>2</sub>, -NR<sup>4</sup>R<sup>5</sup>, NR<sup>4</sup>R<sup>5</sup>(lower alkyl)-, NR<sup>4</sup>R<sup>5</sup>(lower

- 5 -

alkoxy)-, OH, halogeno, -NHC(O)OR<sup>6</sup>, -NHC(O)R<sup>6</sup>, R<sup>7</sup>O<sub>2</sub>SNH-, (R<sup>7</sup>O<sub>2</sub>S)<sub>2</sub>N-, -S(O)<sub>2</sub>NH<sub>2</sub>, -S(O)<sub>2</sub>R<sup>4</sup>, tert-butyldimethyl-silyloxymethyl,

-C(O)R<sup>8</sup>, -CH<sub>2</sub>-N and -C(=O)-N;

A and D are independently a bond; C<sub>3</sub>-C<sub>6</sub> cycloalkylene;

5 C<sub>1</sub>-C<sub>10</sub> alkylene; C<sub>1</sub>-C<sub>10</sub> alkenylene; C<sub>1</sub>-C<sub>10</sub> alkynylene; an alkylene, alkenylene or alkynylene chain as defined substituted by one or more substituents independently selected from the group consisting of phenyl, W-substituted phenyl, heteroaryl and W-substituted heteroaryl, wherein heteroaryl is as defined above; an alkylene, alkenylene or alkynylene

10 chain as defined interrupted by one or more groups independently selected from the group consisting of -O-, -S-, -SO-, -SO<sub>2</sub>-, -NR<sub>8</sub>, -C(O)-, C<sub>3</sub>-C<sub>6</sub> cycloalkylene, phenylene, W-substituted phenylene, heteroarylene and W-substituted heteroarylene; or an interrupted alkylene, alkenylene or alkynylene chain as defined substituted by one or more substituents

15 independently selected from the group consisting of phenyl, W-substituted phenyl, heteroaryl and W-substituted heteroaryl; or R<sup>2</sup>-D is selected from the group consisting of halogeno, OH, lower alkoxy, -OC(O)R<sup>6</sup>, -NR<sup>4</sup>R<sup>5</sup>, -SH and -S(lower alkyl);


R<sup>3</sup> is 1-3 groups independently selected from the group

20 consisting of lower alkyl, lower alkoxy, -COOH, NO<sub>2</sub>, -NR<sup>4</sup>R<sup>5</sup>, OH or halogeno;

R<sup>4</sup> and R<sup>5</sup> are independently selected from H and lower alkyl;


R<sup>6</sup> is lower alkyl, phenyl, R<sup>3</sup>-phenyl, benzyl or R<sup>3</sup>-benzyl;

25 R<sup>7</sup> is OH, lower alkyl, phenyl, benzyl, R<sup>3</sup>-phenyl or R<sup>3</sup>-benzyl;

R<sup>8</sup> is H, OH, alkoxy, phenoxy, benzyloxy, -N4R<sup>5</sup>, lower alkyl, phenyl or R<sup>3</sup>-phenyl;

R<sup>9</sup> is -O-, -CH<sub>2</sub>-, -NH- or -N(lower alkyl)-;


30 or Q and R<sup>2</sup>-D together form the group



wherein R<sup>18</sup> is

-CH-, -C(lower alkyl)-, -CF-, -C(OH)-, -C(C<sub>6</sub>H<sub>5</sub>)-, -C(C<sub>6</sub>H<sub>4</sub>-R<sub>15</sub>)-,


- 6 -



R<sup>16</sup> and R<sup>17</sup> are independently selected from the group consisting of -CH<sub>2</sub>-, -CH(lower alkyl)-, -C(di-lower alkyl)-, -CH=CH- and C(lower alkyl)=CH-; or R<sup>18</sup> together with an adjacent R<sup>16</sup>, or R<sup>18</sup> together with an adjacent R<sup>17</sup>, form a -CH=CH- or a -CH=C(lower alkyl)- group;


5 u and v are independently 0, 1, 2 or 3, provided both are not zero; provided that when R<sup>16</sup> is -CH=CH- or -C(lower alkyl)=CH-, v is 1; provided that when R<sup>17</sup> is -CH=CH- or -C(lower alkyl)=CH-, u is 1; provided that when v is 2 or 3, the R<sup>16</sup>'s can be the same or different; and 10 provided that when u is 2 or 3, the R<sup>17</sup>'s can be the same or different; and q is 0, 1, 2, 3, 4, 5 or 6;

comprising reacting a compound of formula II



wherein A, D, Q, R, R<sup>1</sup> and R<sup>2</sup> are as defined above and G is 15 B, (R<sup>14</sup>)-O- or (R<sup>14</sup>)-S-, wherein B and R<sup>14</sup> are as defined above, with a silylating agent and a fluoride ion catalyst cyclizing agent or, when B is a chiral auxiliary, with a silylating agent and a salt of said chiral auxiliary, provided that where substituents A, D, Q, R, R<sup>1</sup> and R<sup>2</sup> include substituents selected from the group consisting of -NH<sub>2</sub>, -SH and -OH, 20 said substituents are suitably protected prior to reaction with the silylating agent.

A particularly preferred embodiment of the present invention relates to the preparation of compounds of formula I wherein Q is 25 hydrogen and the substituents R<sup>2</sup>-D- and R<sup>1</sup>-A- have trans relative stereochemistry, wherein said process comprises reacting a compound of formula IIa



wherein A, D, R, R<sup>1</sup> and R<sup>2</sup> are as defined above and G is B, 30 (R<sup>14</sup>)-O- or (R<sup>14</sup>)-S-, wherein B and R<sup>14</sup> are as defined above, with a

- 7 -

silylating agent and a fluoride ion catalyst cyclizing agent or, when B is a chiral auxiliary, with a silylating agent and a salt of said chiral auxiliary, provided that where substituents A, D, R, R<sup>1</sup> and R<sup>2</sup> include substituents selected from the group consisting of -NH<sub>2</sub>, -SH and -OH, said

5 substituents are suitably protected prior to reaction with the silylating agent.

Detailed Description

As used herein, the terms  $\beta$ -(substituted-amino)amide,  $\beta$ -(substituted-amino)acid ester, and  $\beta$ -(substituted-amino)thiolcarboxylic acid ester refer to  $\beta$ -aminoamides,  $\beta$ -aminoacid esters, and  $\beta$ -aminothiolcarboxylic acid esters refer to secondary amines, that is, compounds wherein the nitrogen is joined to the  $\beta$ -carbon, to a hydrogen molecule, and to a non-hydrogen substituent.

15 "Aryl" means phenyl, W-substituted phenyl, naphthyl or W-substituted naphthyl.

As used herein, the term "lower alkyl" means straight or branched alkyl chains of 1 to 6 carbon atoms and "lower alkoxy" similarly refers to alkoxy groups having 1 to 6 carbon atoms;

20 "Alkenyl" means straight or branched carbon chains having one or more double bonds in the chain, conjugated or unconjugated, and alkadienyl refers to chains having two double bonds in the chain; similarly, "alkynyl" means straight or branched carbon chains having one or more triple bonds in the chain.

25 Where an alkyl, alkenyl or alkynyl chain joins two other variables and is therefore bivalent, the terms alkylene, alkenylene and alkynylene are used.

30 "Cycloalkyl" means a saturated carbon ring of 3 to 6 carbon atoms, while "cycloalkylene" refers to a corresponding bivalent ring, wherein the points of attachment to other groups include all positional isomers.

"Halogeno" refers to fluorine, chlorine, bromine or iodine radicals.

35 "Heteroaryl" includes all positional isomers for a given heteroaryl group as defined above, for example 2-pyridyl, 3-pyridyl and 4-pyridyl. Benzofused heteroaryl refers to radicals formed by the bonding of a benzene radical to adjacent carbon atoms on a heteroaryl ring;

- 8 -

examples are indolyl, quinolyl, quinazolinyl, quinoxalinyl, benzotriazolyl, indazolyl, benzoxazolyl, benzothienyl and benzofuranyl.

5 "Phenylene" means a bivalent phenyl group bound in an ortho, meta or para orientation and "heteroarylene" similarly means a bivalent heteroaryl group, including all positional isomers.

10 "(Lower alkoxyimino)lower alkyl" refers to the group (C<sub>1</sub>-C<sub>6</sub> lower alkoxy)-N=CH-(C<sub>1</sub>-C<sub>5</sub> lower alkyl). "Lower alkylenedioyl" means radicals of the formula -OC(O)(CH<sub>2</sub>)<sub>1-4</sub>C(O)OH, while "lower alkyl lower alkylenedioyl" means radicals of the formula -OC(O)(CH<sub>2</sub>)<sub>1-4</sub>C(O)O-(lower alkyl).

R<sup>3</sup>-benzyl and R<sup>3</sup>-benzyloxy refer to benzyl and benzyloxy radicals which are substituted on the phenyl ring.

15 The carbon chains as defined in A and D, when substituted by optionally substituted phenyl or heteroaryl groups, may include independent substitution on different carbon atoms, di-substitution on one carbon atom, or both. One skilled in the art will recognize that the number of double or triple bonds present, the replacement of carbon atoms in the chain and the presence of substituents on the carbon atoms in the chain are all dependent on the length of the chain: shorter carbon chains 20 cannot accommodate as many double or triple bonds, carbon replacements or substituents as longer carbon chains can. In general, unsaturated carbon chains contain 1 to 4 double or triple bonds, conjugated or non-conjugated. Where carbon atoms are replaced, 1 to 4 replacement groups can be present. Similarly, when carbon atoms in the 25 chain are substituted, 1 to 4 substituents can be present.

Examples of alkylene chains in A and D are methylene, ethylene, propylene, butylene and decylene.

Examples of unsaturated A and D groups are ethylene and acetylene.

30 Examples of A and D groups wherein the carbon atoms in the chain are replaced are -CH<sub>2</sub>CH<sub>2</sub>O-, -OCH<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>O-, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>O-, -CH<sub>2</sub>-O-CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>O-CH<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>-NH-, -CH<sub>2</sub>CH<sub>2</sub>-N(CH<sub>3</sub>)- and -O-CH<sub>2</sub>C(O)-NH-.

35 Azetidinones prepared by this process, and in particular compounds of formula I, may have at least two asymmetrical carbon atoms and therefore the preparation of all isomers, including diastereomers and rotational isomers, is contemplated. The compounds prepared by this invention include d and l isomers in both pure form and in admixture,

- 9 -

including racemic mixtures. Isomeric compounds prepared by this invention may also include geometric isomers, e.g. when A or D in compounds of formula I contains a double bond.

The order of addition of the components of this process is not critical to the preparation of the azetidinone product. For example, the starting  $\beta$ -(substituted-amino)amide,  $\beta$ -(substituted-amino)acid ester, or  $\beta$ -(substituted-amino)thiolcarboxylic acid ester can first be reacted with the silylating agent and then reacted with the cyclizing agent, or the starting compound can be added to a mixture of the silylating agent and the cyclizing agent.

Silylation is effected by reacting the starting material with a silyl-enol ether silylating agent such as bistrimethylsilyl acetamide (BSA), N-methyl-O-trimethylsilyl acetamide or iso-propenyltrimethylsilane, preferably BSA, in a suitable inert organic solvent at 0°C to 110°C, preferably at about 20°C to 90°C, and more preferably at ambient temperature (e.g., about 25°C). The reaction is preferably carried out in a dry, inert atmosphere, e.g., the solvent is dried, typically with molecular sieves, and the reaction is carried out under nitrogen. When the silylation and cyclization are done sequentially, i.e., the silylating agent is reacted with the starting material first, the silylation reaction can be allowed to continue for up to about two hours, but preferably the cyclization step is carried out immediately after silylation, or the silylating agent and the cyclizing agent are added simultaneously.

Those skilled in the art will recognize that for cyclization to proceed as desired, -NH<sub>2</sub>, -SH and -OH substituents present on the  $\beta$ -(substituted-amino)amide, a  $\beta$ -(substituted-amino)acid ester, or a  $\beta$ -(substituted-amino)thiolcarboxylic acid ester starting material must be converted to groups which will not be silylated, either preferentially or in addition to silylation of the substituted-amino portion of the molecule (i.e., -NH-R in formula II). Suitable protecting groups well known in the art include for -NH<sub>2</sub>: t-butyldimethylsilyl, benzyl, benzoyl and t-butoxycarbonyl; for -SH: triphenylmethyl; and for -OH: lower alkoxy, e.g., methoxy, benzyloxy and t-butyldimethylsilyl.

The source of the fluoride ion used to catalyze the intramolecular cyclization is typically a quaternary alkyl-, aryl-alkyl- or arylalkyl-alkylammonium fluoride salt or a hydrate thereof, or a mixture thereof, wherein alkyl-, aryl-alkyl- or arylalkyl-alkylammonium are as defined above for Z, or is an alkali metal fluoride salt or a hydrate thereof, such as

- 10 -

cesium fluoride or potassium fluoride. When a hydrated quaternary ammonium fluoride salt is used, the reagent is added in a catalytic amount, i.e., about 1 to about 20 mole percent, preferably about 5 mole percent, and when an anhydrous quaternary ammonium fluoride salt is used, it can be added in a catalytic up to a stoichiometric amount. When an alkali metal fluoride salt is used, it is added in catalytic amount up to a stoichiometric amount compared to the starting  $\beta$ -amino compound, depending on the solubility of the reagent in the solvent used (higher solubility requires less reagent). If added to the reaction mixture after the silylation agent, the fluoride reagent is added directly to the reaction mixture resulting from silylation, and is reacted at about 0°C to 110°C, preferably about 20°C to 60°C, for about 0.5 to about 6 hours, preferably about 1 hour. When the silylation reagent and the fluoride reagent are added simultaneously, the reaction is conducted under similar conditions.

Alternatively, for cyclizing compounds wherein the starting  $\beta$ -amino compound contains a chiral auxiliary, a salt of the chiral auxiliary as defined above may be used instead of the fluoride ion to catalyze the reaction. The chiral auxiliary-containing  $\beta$ -amino compound is reacted at room temperature up to reflux temperature for 1 hour with a silylating reagent as described above under an inert atmosphere, e.g., N<sub>2</sub>, in a suitable inert solvent. The chiral auxiliary salt can be added to the reaction mixture at the same time as the silylating agent, or it can be added directly to the reaction mixture resulting from silylation in a catalytic amount or in a stoichiometric amount compared to the starting  $\beta$ -amino compound, and the mixture is reacted at about 0°C to 110°C, preferably about 20° to 60°C for an additional hour.

The azetidinone resulting from either the fluoride ion or chiral auxiliary salt process can be purified by appropriate standard procedures such as column chromatography or crystallization.

The term "suitable inert organic solvent" as used above means any organic solvent or combination of solvents that is unreactive in the reaction being conducted and is a solvent for the reactants. Typical suitable solvents are halogenated compounds such as dichloromethane; heterocyclic compounds such as tetrahydrofuran (THF); DMSO; dimethyl-formamide (DMF); acetonitrile; and carbocyclic aromatics such as toluene. Preferred are toluene, THF and dichloromethane.

Starting  $\beta$ -(substituted-amino)amides,  $\beta$ -(substituted-amino)acid esters and  $\beta$ -(substituted-amino)thiolcarboxylic acid esters are


- 11 -

known or can be prepared by one skilled in the art using known methods.  $\beta$ -aminoamide compounds of formula II and IIa, wherein B is a radical of a chiral auxiliary, are disclosed in WO 93/02048.

5 The chiral auxiliary salt is prepared by known procedures, for example the tetra n-butylammonium salt of a 2-oxazolidinone can be prepared by deprotonating the chiral auxiliary with a strong base such as sodium hydride in an inert solvent such as THF at 0°C for 30 minutes, then adding the tetra n-butylammonium chloride or bromide salt and stirring for an additional 30 minutes.

10 An especially preferred embodiment of the process of this invention comprises the reaction of a  $\beta$ -(substituted-amino)amide of formula IIb, i.e., a compound of formula IIa wherein G is B', a deprotonated chiral auxiliary as defined above; use of a chiral auxiliary as part of the starting  $\beta$ -(substituted-amino)amide is particularly desirable because the  
15 salt of the chiral auxiliary resulting from the process can be recovered for reuse. A more preferred embodiment, exemplified by the preparation of compounds of formula I wherein the C-3 and C-4 substituents have trans relative stereochemistry, is shown in Scheme A. Said process comprises the reaction of a compound of formula IIb, wherein A, D, X, Y, R, R<sup>1</sup>, R<sup>2</sup>,  
20 R<sup>12</sup> and R<sup>13</sup> are as defined above, with a silylating agent and a fluoride ion to prepare a compound of formula Ia, wherein Q is hydrogen.

Scheme A:



In the reaction shown in Scheme A, it is preferred that in the starting  
25 material of compound IIb, X and Y are each oxygen and R<sup>12</sup> is hydrogen. More preferred compounds of formula IIb are those wherein X and Y are each oxygen, R<sup>12</sup> is hydrogen and R<sup>13</sup> is phenyl, benzyl or isopropyl. A preferred silylating agent is BSA, and a preferred source of fluoride ion is tetra n-butylammonium fluoride or a hydrate thereof, preferably its trihydrate.

30 The following examples illustrate the process of this invention. Although the examples are directed to C-3, C-4 disubstituted compounds and the stereochemistry of the reactants and intermediates


- 12 -

are indicated in the various depicted structural formulas in the following examples, it is to be understood that the process of this invention is operative for azetidinones regardless of stereochemistry, and involves merely the selection of reactants having the desired racemic or 5 stereochemical configuration and the selection of reaction conditions which result in the desired configuration in the product.

Preparation 1




Step A: To a stirred suspension of 5-phenyl valeric acid (50 g, 281 mmol) in toluene (50 mL), add  $\text{SOCl}_2$  (40 mL, 548 mmol). Heat the mixture to 90°C in an oil bath for 3 hours. Distill off the excess  $\text{SOCl}_2$  as an azeotropic mixture with toluene under reduced pressure. Again add toluene (50 mL), and distill off both toluene and any residual  $\text{SOCl}_2$  under reduced pressure. Add  $\text{CH}_2\text{Cl}_2$  (200 mL) to the crude acid chloride in the reaction flask and use the resulting solution directly in Step B.




Step B: To  $\text{CH}_2\text{Cl}_2$  (600 mL), add (4S)-4-phenyl-2-oxazolidinone (38.6 g, 236.8 mmol), triethylamine (TEA) (80 mL, 574 mmol) and 4-dimethyl-amino pyridine (DMAP) (2 g, 16.4 mmol). Stir the mixture and cool in an ice-bath to ~5°C. Slowly add the solution of Step A, maintaining the temperature at ~5°C. After the addition is complete, allow the mixture to warm to room temperature and stir overnight. Add water (400 mL) and stir for 30 minutes to destroy the excess acid chloride. Separate the organic layer and extract the aqueous layer with  $\text{CH}_2\text{Cl}_2$  (200 mL). Combine the organic layers, wash with aqueous 2N  $\text{H}_2\text{SO}_4$  (600 mL), followed by brine solution (200 mL), saturated  $\text{NaHCO}_3$  (400 mL) and brine solution (200 mL). Concentrate the organic layer under reduced pressure, and dissolve the resultant residue in  $\text{CH}_2\text{Cl}_2$  to a total volume of 1000 mL. Use this solution in Step C.

- 13 -



Step C: Cool a solution of the product of Step B (238 mL, 56.4 mmol) in  $\text{CH}_2\text{Cl}_2$  to  $-20^\circ\text{C}$  to  $-25^\circ\text{C}$ . Slowly add a 1 molar solution of  $\text{TiCl}_4$  in  $\text{CH}_2\text{Cl}_2$  (56 mL, 56 mmol), while maintaining the temperature below 5  $-20^\circ\text{C}$ . After the addition is complete, stir for 10 min. at that temperature. Slowly add Hunig's base (*N,N*-diisopropylethylamine) (19.5 mL, 112 mmol); a characteristic dark-red color is observed. Stir the mixture for 30 min. at  $-20^\circ$  to  $-25^\circ\text{C}$ . Slowly add a solution of Schiff's base derived from anisaldehyde and *p*-anisidine (26.86 g, 111.5 mmol) in  $\text{CH}_2\text{Cl}_2$  (200 mL) 10 and stir for 1 hour while maintaining the temperature below  $-20^\circ\text{C}$ . Quench the reaction by adding a solution of glacial acetic acid (18 mL) in  $\text{CH}_2\text{Cl}_2$  (32 mL), maintaining the temperature below  $-20^\circ\text{C}$ . Continue stirring for 30 min., then pour the reaction mixture into aqueous 2N  $\text{H}_2\text{SO}_4$  (600 mL) at  $0^\circ\text{C}$ . Stir for 30 minutes, then add ethyl acetate ( $\text{EtOAc}$ ) (1 L) 15 and stir until the organic layer separates cleanly. Separate the organic layer, extract the aqueous layer with  $\text{CH}_2\text{Cl}_2$  (50 mL), combine the organic layers and wash with saturated  $\text{NaHCO}_3$  solution, followed by brine solution. Concentrate the organic layer under reduced pressure and crystallize the residue from  $\text{EtOAc}$  and hexane to obtain the pure  $\beta$ -amino carbonyl compound of formula 1. 20

Example 1To a stirred suspension of the  $\beta$ -aminoamide of formula 1

- 14 -

(15 g, 26.6 mmol) in sieve-dried toluene (225 mL) at about 90°C under a N<sub>2</sub> atmosphere, add BSA (10 mL, 40.5 mmol) and heat the reaction mixture for about one hour at about 90°C. Add tetra n-butylammonium fluoride trihydrate (420 mg, 1.33 mmol) and heat for one hour at 90°C to 5 obtain 10.2 g of the compound of formula 1a (96% yield), 99% de, 99.9% ee.

Example 1A

To a stirred suspension of the  $\beta$ -aminoamide of formula 1 as shown in Example 1 (20 g, 35.5 mmol) in sieve-dried toluene (400 mL) at 10 about 90°C under a N<sub>2</sub> atmosphere, add BSA (15 mL, 60.75 mmol) and heat at about 90°C for 2 hours. Cool to 55-60°C, add tetra n-butylammonium fluoride trihydrate (560 mg, 1.78 mmol) and heat for 2 hours at 55-60°C to obtain 13.62 g of the compound of formula 1a as shown in Example 1 (96% yield), 99% de, 99.9% ee.

15

Example 1B


To a stirred suspension of the  $\beta$ -aminoamide of formula 1 as shown in Example 1 (20 g, 35.5 mmol) in toluene (200 mL) at room 20 temperature, add BSA (15 mL, 60.75 mmol), followed by tetra n-butylammonium fluoride trihydrate (112 mg, 0.35 mmol). Monitor the reaction progress by HPLC; after 1.5 h, obtain compound 1a (14.2 g, 99.8% yield) 99% de, 99.9% ee.

Example 1C

25 To a stirred suspension of the  $\beta$ -aminoamide of formula 1 as shown in Example 1 (5.014 g, 8.9 mmol) in DMSO (35 mL) at room temperature, add BSA (3.8 mL, 15.2 mmol), followed by CsF (68 mg, 0.445 mmol). Monitor the reaction progress by HPLC; add additional BSA (2 mL) and stir 4 h to obtain compound 1a (2.8 g, 79% yield) 96% de, 30 99.9% ee.


- 15 -

### Example 2



To a stirred suspension of the  $\beta$ -aminoamide of formula 2 (5 g, 8.9 mmol) in dry THF (75 mL), add BSA (5.4 mL, 21.85 mmol), then reflux under a  $N_2$  atmosphere for 16 hours. Add anhydrous CsF (1.35 g, 8.9 mmol) and reflux for 6 hours to obtain 3.42 g of the compound of formula 1b (96% yield), 99% de.

### Example 2A




Step 1: To a stirred solution of (R)-4-phenyl-2-oxazolidinone (174 mg, 1.06 mmol) in THF (4 mL) at 0°C, add NaH (4.3 mg, 60% emulsion in oil, 0.106 mmol). Allow the temperature to rise to room temperature over 30 min., then add tetra n-butylammonium bromide (34 mg, 0.106 mmol) to the mixture and stir for another 30 min. to obtain (R)-4-phenyl-2-oxazolidinone tetra n-butylammonium salt.

Step 2: To a stirred solution of the  $\beta$ -aminoamide of formula 2 (0.604 g, 1.06 mmol) in sieve-dried THF (8 mL) at reflux under an  $N_2$  atmosphere, add BSA (0.66 mL, 2.66 mmol). Heat to reflux for 1 h, then add a solution of the product of Step 1 (0.106 mmol) in THF (4 mL). Continue heating for 1 h to obtain the product 1b (0.37 g, 87% yield) 97% de, 99.9% ee.


In a similar manner, at reflux or at room temperature, use (S)-4-phenyl-2-oxazolidinone tetra n-butylammonium salt and compound 1 of Preparation 1 to prepare compound 1a.

- 16 -

We claim:

1. A process for preparing an azetidinone comprising reacting a  $\beta$ -(substituted-amino)amide, a  $\beta$ -(substituted-amino)-acid ester, or a  $\beta$ -(substituted-amino)thiolcarboxylic acid ester with a silylating agent and a cyclizing agent.
2. A process of claim 1 comprising reacting a silylating agent and a fluoride ion catalyst cyclizing agent with a suitably protected compound selected from the group consisting of
  - i) a  $\beta$ -(substituted-amino)amide, wherein the carbamoyl portion is  $B-C(O)-$ , wherein B is a deprotonated chiral auxiliary selected from the group consisting of
 
- 15 15 wherein X is  $-O-$ ,  $-S-$  or  $-N(C_1-C_6\text{ alkyl})-$ ; Y is  $=O$  or  $=S$ ; and R<sup>12</sup> and R<sup>13</sup> are independently selected from the group consisting of C<sub>1</sub>-C<sub>6</sub> alkyl, phenyl, naphthyl, substituted phenyl, substituted naphthyl, lower alkoxy carbonyl and benzyl, wherein the substituents on the phenyl and naphthyl are 1-3 substituents selected from the group consisting of lower alkyl, phenyl and benzyl, or wherein one of R<sup>12</sup> or R<sup>13</sup> is as defined above and the other is hydrogen; or B is  $(R^{14})(R^{15})N-$ , wherein R<sup>14</sup> and R<sup>15</sup> are independently selected from the group consisting of lower alkyl, aryl and benzyl;
- 20 20 ii) a  $\beta$ -(substituted-amino)acid ester, wherein the carboxylic acid ester portion is  $R^{14}-O-C(O)-$ , wherein R<sup>14</sup> is lower alkyl, aryl or benzyl; and
- 25 25 iii) a  $\beta$ -(substituted-amino)thiolcarboxylic acid ester, wherein the thiolcarboxylic acid ester portion is  $R^{14}-S-C(O)-$ , wherein R<sup>14</sup> is lower alkyl, aryl or benzyl.
- 30 30 3. A process of claim 1 for preparing an azetidinone comprising reacting a suitably protected  $\beta$ -(substituted-amino)amide, wherein the carbamoyl portion is  $B-C(O)-$ , wherein B is a deprotonated chiral auxiliary selected from the group consisting of

- 17 -




wherein X is -O- or -S- or -N(C<sub>1</sub>-C<sub>6</sub> alkyl)-; Y is =O or =S; and R<sup>12</sup> and R<sup>13</sup> are independently selected from the group consisting of C<sub>1</sub>-C<sub>6</sub> alkyl, phenyl, naphthyl, substituted phenyl, substituted naphthyl, lower

5 alkoxy carbonyl and benzyl, wherein the substituents on the phenyl and naphthyl are 1-3 substituents selected from the group consisting of lower alkyl, phenyl and benzyl, or wherein one of R<sup>12</sup> or R<sup>13</sup> is as defined above and the other is hydrogen;

with a silylating agent and a cyclizing agent which is a


10 monovalent salt of the formula



wherein X, Y, R<sup>12</sup> and R<sup>13</sup> are as defined above or each of R<sup>12</sup> and R<sup>13</sup> is hydrogen, and Z is selected from the group consisting of quaternary ammonium cations and alkali metals.

15

4. A process of any of claims 1, 2 or 3 for preparing an azetidinone represented by the formula



wherein


20 Q is hydrogen, lower alkyl, phenyl-(CH<sub>2</sub>)<sub>0-3</sub>- or (W-substituted)phenyl-(CH<sub>2</sub>)<sub>0-3</sub>;

R is phenyl, W-substituted phenyl, naphthyl, W-substituted naphthyl, benzodioxolyl, heteroaryl, W-substituted heteroaryl, benzofused heteroaryl and W-substituted benzofused heteroaryl, wherein heteroaryl is selected from the group consisting of pyrrolyl, pyridinyl, pyrimidinyl, pyrazinyl, triazinyl, imidazolyl, thiazolyl, pyrazolyl, thienyl, oxazolyl and furanyl, and for nitrogen-containing heteroaryls, the N-oxides thereof;

R<sup>1</sup> and R<sup>2</sup> are independently selected from H or R;

- 18 -

W is 1 to 3 substituents independently selected from the group consisting of lower alkyl, hydroxy lower alkyl, lower alkoxy, alkoxyalkyl, alkoxyalkoxy, alkoxy carbonylalkoxy, (lower alkoxyimino)-lower alkyl, lower alkylene dioyl, lower alkyl lower alkylene dioyl, allyloxy, -CF<sub>3</sub>, -OCF<sub>3</sub>, benzyl, R<sup>3</sup>-benzyl, benzyloxy, R<sup>3</sup>-benzyloxy, phenoxy, R<sup>3</sup>-phenoxy, dioxolanyl, NO<sub>2</sub>, -NR<sup>4</sup>R<sup>5</sup>, NR<sup>4</sup>R<sup>5</sup>(lower alkyl)-, NR<sup>4</sup>R<sup>5</sup>(lower alkoxy)-, OH, halogeno, -NHC(O)OR<sup>6</sup>, -NHC(O)R<sup>6</sup>, R<sup>7</sup>O<sub>2</sub>SNH-, (R<sup>7</sup>O<sub>2</sub>S)<sub>2</sub>N-, -S(O)<sub>2</sub>NH<sub>2</sub>, -S(O)<sub>2</sub>R<sup>4</sup>, tert-butyldimethyl-silyloxy methyl,




10 A and D are independently a bond; C<sub>3</sub>-C<sub>6</sub> cycloalkylene; C<sub>1</sub>-C<sub>10</sub> alkylene; C<sub>1</sub>-C<sub>10</sub> alkenylene; C<sub>1</sub>-C<sub>10</sub> alkynylene; an alkylene, alkenylene or alkynylene chain as defined substituted by one or more substituents independently selected from the group consisting of phenyl, W-substituted phenyl, heteroaryl and W-substituted heteroaryl, wherein heteroaryl is as defined above; an alkylene, alkenylene or alkynylene chain as defined interrupted by one or more groups independently selected from the group consisting of -O-, -S-, -SO-, -SO<sub>2</sub>-, -NR<sub>8</sub>, -C(O)-, C<sub>3</sub>-C<sub>6</sub> cycloalkylene, phenylene, W-substituted phenylene, heteroarylene and W-substituted heteroarylene; or an interrupted alkylene, alkenylene or alkynylene chain as defined substituted by one or more substituents independently selected from the group consisting of phenyl, W-substituted phenyl, heteroaryl and W-substituted heteroaryl; or R<sup>2</sup>-D is selected from the group consisting of halogeno, OH, lower alkoxy, -OC(O)R<sup>6</sup>, -NR<sup>4</sup>R<sup>5</sup>, -SH and -S(lower alkyl);

25 R<sup>3</sup> is 1-3 groups independently selected from the group consisting of lower alkyl, lower alkoxy, -COOH, NO<sub>2</sub>, -NR<sup>4</sup>R<sup>5</sup>, OH or halogeno;

    R<sup>4</sup> and R<sup>5</sup> are independently selected from H and lower alkyl;

30 R<sup>6</sup> is lower alkyl, phenyl, R<sup>3</sup>-phenyl, benzyl or R<sup>3</sup>-benzyl;


    R<sup>7</sup> is OH, lower alkyl, phenyl, benzyl, R<sup>3</sup>-phenyl or R<sup>3</sup>-benzyl;

    R<sup>8</sup> is H, OH, alkoxy, phenoxy, benzyloxy, , -NR<sup>4</sup>R<sup>5</sup>, lower alkyl, phenyl or R<sup>3</sup>-phenyl;

35 R<sup>9</sup> is -O-, -CH<sub>2</sub>-, -NH- or -N(lower alkyl)-;

    or Q and R<sup>2</sup>-D- together form the group

- 19 -




wherein  $R^{18}$  is

$\begin{array}{l} -CH-, -C(lower\ alkyl)-, -CF-, -C(OH)-, -C(C_6H_5)-, -C(C_6H_4-R_{15})-, \\ -N- \text{ or } \begin{array}{c} | \\ N \\ | \\ O^- \end{array} \end{array}$


5  $R^{16}$  and  $R^{17}$  are independently selected from the group consisting of  $-CH_2-$ ,  $-CH(lower\ alkyl)-$ ,  $-C(di-lower\ alkyl)-$ ,  $-CH=CH-$  and  $C(lower\ alkyl)=CH-$ ; or  $R^{18}$  together with an adjacent  $R^{16}$ , or  $R^{18}$  together with an adjacent  $R^{17}$ , form a  $-CH=CH-$  or a  $-CH=C(lower\ alkyl)-$  group;

10  $u$  and  $v$  are independently 0, 1, 2 or 3, provided both are not zero; provided that when  $R^{16}$  is  $-CH=CH-$  or  $-C(lower\ alkyl)=CH-$ ,  $v$  is 1; provided that when  $R^{17}$  is  $-CH=CH-$  or  $-C(lower\ alkyl)=CH-$ ,  $u$  is 1; provided that when  $v$  is 2 or 3, the  $R^{16}$ 's can be the same or different; and provided that when  $u$  is 2 or 3, the  $R^{17}$ 's can be the same or different; and  $q$  is 0, 1, 2, 3, 4, 5 or 6;

15 comprising reacting a compound of formula II



wherein A, D, Q, R,  $R^1$  and  $R^2$  are as defined above and G is B,  $(R^{14})-O-$  or  $(R^{14})-S-$ , wherein B is a deprotonated chiral auxiliary selected from the group consisting of




20 wherein X is  $-O-$ ,  $-S-$  or  $-N(C_1C_6\ alkyl)-$ ; Y is  $=O$  or  $=S$ ; and  $R^{12}$  and  $R^{13}$  are independently selected from the group consisting of  $C_1-C_6$  alkyl, phenyl, naphthyl, substituted phenyl, substituted naphthyl, lower alkoxy carbonyl and benzyl, wherein the substituents on the phenyl and naphthyl are 1-3 substituents selected from the group consisting of lower alkyl, phenyl and benzyl, or wherein one of  $R^{12}$  or  $R^{13}$  is as defined above and the other is hydrogen; or B is  $(R^{14})(R^{15})N-$ ; and

- 20 -


R<sup>14</sup> and R<sup>15</sup> are independently selected from the group consisting of lower alkyl, aryl and benzyl; with a silylating agent and a fluoride ion catalyst cyclizing agent or, when B is a deprotonated chiral auxiliary as defined above, with a silylating agent and a salt of said chiral auxiliary, provided that where substituents A, D, Q, R, R<sup>1</sup> and R<sup>2</sup> include substituents selected from the group consisting of -NH<sub>2</sub>, -SH and -OH, said substituents are suitably protected prior to reaction with the silylating agent.

10 5. A process of claim 4 comprising reacting a compound of the formula




wherein A, D, R, R<sup>1</sup>, R<sup>2</sup>, and G are as defined in claim 4, with a silylating agent and a fluoride ion catalyst cyclizing agent.

15 6. A process of claim 4 comprising reacting a compound of the formula




wherein A, D, R, R<sup>1</sup>, and R<sup>2</sup> are as defined in claim 4 and G' is B', wherein 20 B' is a deprotonated chiral auxiliary selected from the group consisting of



wherein X is -O-, -S- or -N(C<sub>1</sub>-C<sub>6</sub> alkyl)-; Y is =O or =S; and R<sup>12</sup> and R<sup>13</sup> are independently selected from the group consisting of C<sub>1</sub>-C<sub>6</sub> alkyl, phenyl, naphthyl, substituted phenyl, substituted naphthyl, lower 25 alkoxy carbonyl and benzyl, wherein the substituents on the phenyl and naphthyl are 1-3 substituents selected from the group consisting of lower alkyl, phenyl and benzyl, or wherein one of R<sup>12</sup> or R<sup>13</sup> is as defined above and the other is hydrogen;

- 21 -

with a silylating agent and a cyclizing agent which is a monovalent salt of the formula



wherein X, Y, R<sup>12</sup> and R<sup>13</sup> are as defined above or each of R<sup>12</sup> and R<sup>13</sup> is 5 hydrogen, and Z is selected from the group consisting of quaternary ammonium cations and alkali metals.

7. A process of any of claims 1, 2, 3, 4, 5 or 6 wherein the silylating agent is a silyl-enol ether.

10 8. A process of any of claims 1, 2, 3, 4, 5, 6 or 7 wherein the silylating agent is bistrimethylsilylacetamide, N-methyl-O-trimethyl silylacetamide or isopropenyltrimethylsilane.


15 9. A process of any of claims 1, 2, 4, 5, 7 or 8 wherein the fluoride ion catalyst is selected from the group consisting of a quaternary alkylammonium fluoride salt or hydrate thereof, a quaternary arylalkylammonium fluoride salt or hydrate thereof, a quaternary arylalkyl-alkylammonium fluoride salt or hydrate thereof, or a mixture thereof, and an 20 alkali metal fluoride salt or hydrate thereof.

10. A process of any of claims 1, 2, 4, 5, 7, 8 or 9 wherein the fluoride ion catalyst is tetra n-butylammonium fluoride, cesium fluoride, potassium fluoride, or a hydrate thereof.

25 11. A process of any of claims 1, 2 or 3 comprising reacting a  $\beta$ -(substituted-amino)amide, a  $\beta$ -(substituted-amino)acid ester, or a  $\beta$ -(substituted-amino)thiolcarboxylic acid ester with a silylating agent.

30 12. A process of any of claims 1, 2, 4, 5, 7, 8, 9, 10 or 11 comprising reacting a  $\beta$ -(substituted-amino)amide of the formula


- 22 -




wherein X and Y are each oxygen, R<sup>12</sup> is hydrogen and R<sup>13</sup> is phenyl, benzyl or isopropyl, with bistrimethylsilylacetamide and with tetra n-butylammonium fluoride, cesium fluoride or a hydrate thereof.

5

13. A process of claim 12 for preparing a compound of the formula




comprising reacting a  $\beta$ -(substituted-amino)amide of the formula



10

with bistrimethylsilylacetamide and with tetra n-butylammonium fluoride, cesium fluoride or a hydrate thereof.


14. A process of claim 3 or 6 comprising reacting a  $\beta$ - (substituted-amino)amide of the formula




with bistrimethylsilylacetamide and (S)-4-phenyl-2-oxazolidinone tetra n-butylammonium salt.

20 15. A process of claim 14 for preparing a compound of the formula

- 23 -



comprising reacting a  $\beta$ -(substituted-amino)amide of the formula



with bistrimethylsilylacetamide and (S)-4-phenyl-2-oxazolidinone tetra n-  
5 butylammonium salt.

## INTERNATIONAL SEARCH REPORT

Int. Application No

PCT/US 94/07291

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 C07D205/08

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US,A,4 876 365 (M.P. KIRKUP ET AL.) 24 October 1989 *the whole document, especially example 4* ---	1-15
Y	WO,A,93 02048 (SCHERING CORPORATION) 4 February 1993 cited in the application * pages 97-99 (example 40); claims * ---	1-15
A	TETRAHEDRON, vol.39, no.6, 1983, GREAT BRITAIN pages 999 - 1009 R.J.P. CORRIU ET AL. 'Activation of silicon-hydrogen, silicon-oxygen, silicon-nitrogen bonds in heterogeneous phase.' * the whole article, especially page 1007, scheme 2 * --- -/-	1-15

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search  7 October 1994	Date of mailing of the international search report  13. 10. 94
Name and mailing address of the ISA  European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer  Chouly, J

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 94/07291

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>TETRAHEDRON LETTERS, vol.29, no.16, 1988, GREAT BRITAIN pages 1931 - 1934</p> <p>D. BOUZARD ET AL. 'Utilisation du fluorure de tetrabutylammonium comme agent de cyclisation dans la synthèse d'antibactériens dérivés d'acide pyridone-4-carboxylique-3.' see the whole document ---</p>	1-15
A	<p>EP,A,0 333 268 (MERCK &amp; CO., INC.) 20 September 1989 * page 4, chart A; page 9, step F. *</p> <p>---</p>	1-15
A	<p>EP,A,0 415 487 (MERCK &amp; CO., INC.) 6 March 1991 * pages 13-14, scheme I *</p> <p>-----</p>	1-15

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/US 94/07291

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US-A-4876365	24-10-89	AU-A-	4809790	26-06-90
		CA-A-	2004355	05-06-90
		EP-A-	0373448	20-06-90
		EP-A-	0447456	25-09-91
		JP-T-	4500077	09-01-92
		WO-A-	9006316	14-06-90
-----	-----	-----	-----	-----
WO-A-9302048	04-02-93	AU-A-	2398092	23-02-93
		CA-A-	2114007	04-02-93
		CN-A-	1069024	17-02-93
		EP-A-	0524595	27-01-93
		EP-A-	0596015	11-05-94
		US-A-	5306817	26-04-94
-----	-----	-----	-----	-----
EP-A-0333268	20-09-89	JP-A-	1275588	06-11-89
		US-A-	5145957	08-09-92
-----	-----	-----	-----	-----
EP-A-0415487	06-03-91	US-A-	4983597	08-01-91
		CA-A-	2024267	01-03-91
		JP-A-	3093770	18-04-91
-----	-----	-----	-----	-----